Patents by Inventor Paulin Essone Ndong

Paulin Essone Ndong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for diagnosing tuberculosis disease by detecting induced markers after stimulation of T-cells with antigens
    Patent number: 10001481
    Abstract: A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-?, TNF-?, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-?2, fractalkine, IFN-?, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1?, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1?, IL-6, GM-CSF, IL-1?, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-?, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject.
    Type: Grant
    Filed: May 27, 2013
    Date of Patent: June 19, 2018
    Assignee: Stellenbosch University
    Inventors: Gerhard Walzl, Novel Njweipi Chegou, Paulin Essone Ndong
  • Method for Diagnosing Tuberculosis Disease by Detecting Induced Markers After Stimulation of T-Cells With Antigens
    Publication number: 20150141279
    Abstract: A method of diagnosing tuberculosis (TB) disease and distinguishing between active TB and latent TB infection in a subject is described herein. A sample from the subject is stimulated with at least one Mycobacterium tuberculosis (M.tb) infection phase-dependent antigen selected from Rv0081, Rv2032, Rv1737c, Rv2389c, Rv0867c, TB18.2, Rv2099c, Rv1733c, M.tb PPD, PHA and ESAT-6/CFP-10 and the presence of at least one host marker in the sample is detected, the host marker being selected from EGF, TGF-?, TNF-?, VEGF, RANTES, IL-12(p40), IL-12(p70), IL-10, IP-10, IFN-?2, fractalkine, IFN-?, IL-13, IL-1Ra, IL-3, IL-4, IL-5, MIP-1?, ENA-78, BCA-1, TARC, X6-Ckine, eotaxin, eotaxin-2, SCF, APOA-1, APOE, HPALBN, HCF, Serum amyloid protein A (SAA), C-reactive protein (CRP), serum amyloid protein P (SAP), TIMP-1, MIP-1?, IL-6, GM-CSF, IL-1?, MMP-9, MMP-2, MCP-1, TRAIL, IL-15, IL-17F, IL-22, TNF-?, MCP-2 and MCP-4. Additional host markers may also be detected in an unstimulated sample from the subject.
    Type: Application
    Filed: May 27, 2013
    Publication date: May 21, 2015
    Applicant: Stellenbosch University
    Inventors: Gerhard Walzl, Novel Njweipi Chegou, Paulin Essone Ndong